Foxp3 + regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma

Liver International

Volumn 32, Issue 4, 2012, Pages 644-655

  Wang, Fengmei ^a   Jing, Xiang ^b   Li, Ge ^c   Wang, Tao ^a   Yang, Bin ^d   Zhu, Zhengyan ^d   Gao, Yingtang ^d   Zhang, Qin ^b   Yang, Yankai ^a   Wang, Yijun ^b   Wang, Peng ^d   Du, Zhi ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b THIRD CENTRAL HOSPITAL OF TIANJIN   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Tianjin Key Laboratory of Artificial Cell   (China)

Author keywords

Hepatitis B viruses; Hepatocellular carcinoma; Prognosis; Regulatory T cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84858285901     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02675.x     Document Type: Article

References (33)

1. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-89.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-3.
3. Zhai Y, Zhou G, Deng G, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006; 130: 2001-9.
4. Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology. J Clin Oncol 2008; 26: 313-25.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
7. Kuang SY, Jackson PE, Wang JB, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 2004; 101: 3575-80.
8. Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005; 54: 1162-8.
9. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
10. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
11. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
12. Stoop JN, Van Der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
13. Yang G, Liu A, Xie Q, et al. Association of CD4 + CD25 + Foxp3 + regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007; 19: 133-40.
14. Franzese O, Kennedy PT, Gehring AJ, et al. Modulation of the CD8 + -T-cell response by CD4 + CD25 + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-8.
15. Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52: 330-9.
16. Cai MY, Xu YF, Qiu SJ, et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 2009; 15: 4686-93.
17. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.
18. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-93.
19. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-9.
20. Ju MJ, Qiu SJ, Gao Q, et al. Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 2009; 100: 1267-74.
21. Zhou L, Fu JL, Lu YY, et al. Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol 2010; 45: 968-78.
22. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 2(Suppl 1): S115-20.
23. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumours of the Digestive System, Lyon: International Agency for Research on Cancer, 2000; 159-72.
24. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
25. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
26. Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16: 637-50.
27. Chang KM. Regulatory T cells and the liver: a new piece of the puzzle. Hepatology 2005; 41: 700-2.
28. Lin CY, Tsai MC, Huang CT, et al. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. J Viral Hepat 2007; 14: 503-11.
29. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4 + CD25 + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.
30. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3 + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-11.
31. Peng G, Li S, Wu W, et al. Circulating CD4 + CD25 + regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123: 57-65.
32. Stoop JN, Claassen MA, Woltman AM, et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol 2008; 129: 419-27.
33. Stoop JN, Van Der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141-8.